Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis
- 1 July 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 16 (7), 1037-1042
- https://doi.org/10.2215/cjn.03500321
Abstract
Background and objectives Coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients on maintenance hemodialysis and the factors associated with it. Design, setting, participants, & measurements The study included 56 patients on maintenance hemodialysis (dialysis group) and a control group composed of 95 health care workers. All participants had received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine. The serology testing was done using Quant II IgG anti-Spike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay by Abbott a median of 30 days after receipt of the second dose of the vaccine. Results All subjects in the control group developed an antibody response compared with 96% (54 of 56) positive responders in the dialysis group. The IgG levels in the dialysis group (median, 2900; interquartile range, 1128–5651) were significantly lower than in the control group (median, 7401; interquartile range, 3687–15,471). A Mann–Whitney U test indicated that this difference was statistically significant (U=1238; PP=0.004) and for the dialysis group compared with the control group (odds ratio, 2.7; 95% confidence interval, 1.13 to 7.51; P=0.05). Within the dialysis group, older age and lower lymphocyte count were associated with antibody response in the lower quartile (odds ratio, 1.22 per 1-year older; 95% confidence interval, 1.13 to 1.68; P=0.03 and odds ratio, 0.83 per 10-e3/µl-higher lymphocyte count; 95% confidence interval, 0.58 to 0.97; P=0.05). Conclusions Although most patients on maintenance hemodialysis developed a substantial humoral response following the BNT162b2 vaccine, it was significantly lower than controls. Age was an important factor in the humoral response, regardless of chronic medical conditions.Keywords
This publication has 19 references indexed in Scilit:
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesThe New England Journal of Medicine, 2020
- Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional studyThe Lancet, 2020
- Immunological considerations for COVID-19 vaccine strategiesNature Reviews Immunology, 2020
- Treatment impact on COVID-19 evolution in hemodialysis patientsKidney International, 2020
- Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysisJournal of Nephrology, 2019
- High-Dose Seasonal Influenza Vaccine in Patients Undergoing DialysisClinical Journal of the American Society of Nephrology, 2018
- The CD8 T Cell Response to Respiratory Virus InfectionsFrontiers in Immunology, 2018
- Immune cell dysfunction and inflammation in end-stage renal diseaseNature Reviews Nephrology, 2013
- Aspects of Immune Dysfunction in End-stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2008
- THE RÔLE OF THE LYMPHOCYTE IN ANTIBODY FORMATIONThe Journal of Experimental Medicine, 1945